SMA Type 2

Disease Overview

Spinal Muscular Atrophy (SMA) Type 2 is a rare genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to the degeneration of motor neurons in the spinal cord. This intermediate form of SMA typically manifests between 6 and 18 months of age, causing significant motor function impairment and developmental challenges.

Disease Category

Neuromuscular Disorder Genetic Disorder Autosomal Recessive Condition

Synonyms

Intermediate Spinal Muscular Atrophy
SMA II
Juvenile Spinal Muscular Atrophy
Chromosome 5q Spinal Muscular Atrophy

Signs & Symptoms

Symptom onset between 6 and 18 months of age
Progressive muscle weakness, primarily in proximal muscles
Delayed motor milestones
Fasciculations (muscle twitches) in the tongue
Ability to sit independently but difficulty standing or walking
Respiratory complications
Scoliosis
Contractures
Reduced muscle tone (hypotonia)
Potential feeding difficulties

Causes

Genetic mutation in the SMN1 gene on chromosome 5q
Reduced production of survival motor neuron (SMN) protein
Autosomal recessive inheritance pattern
Requires inheritance of mutated gene from both parents

Affected Populations

Incidence: Approximately 1 in 10,000 live births
Equal prevalence in males and females
Typically diagnosed in infancy or early childhood
Affects all ethnic groups

Disorders with Similar Symptoms

Muscular Dystrophy
Congenital Myopathies
Guillain-Barre Syndrome
Other forms of Spinal Muscular Atrophy
Peripheral Neuropathies
Mitochondrial Disorders

Diagnosis

Comprehensive medical history and physical examination
Genetic testing for SMN1 gene mutations
Electromyography (EMG)
Nerve conduction velocity (NCV) tests
Muscle biopsy (in atypical cases)
Creatine kinase (CK) level assessment
Genetic counseling

Standard Therapies

Nusinersen (Spinraza): Antisense oligonucleotide therapy
Onasemnogene abeparvovec (Zolgensma): Gene replacement therapy
Risdiplam (Evrysdi): Oral SMN2 gene splicing modifier
Supportive therapies:
- Physical therapy
- Occupational therapy
- Respiratory support
- Nutritional management
- Orthopedic interventions
- Assistive devices

Clinical Trials and Studies

Ongoing research into gene therapy
Exploring novel pharmacological interventions
Investigating potential combination therapies
Studying long-term outcomes and treatment efficacy
Resources: ClinicalTrials.gov

References

National Institutes of Health (NIH)
Genetics Home Reference
Cure SMA Research
Journal of Neuromuscular Diseases

Programs & Resources

Cure SMA
Muscular Dystrophy Association (MDA)
National Organization for Rare Disorders (NORD)
Parent Project Muscular Dystrophy
International SMA Research Consortium

Complete Report

Spinal Muscular Atrophy Type 2 is a complex genetic neuromuscular disorder requiring comprehensive, multidisciplinary management. Early diagnosis, genetic counseling, and emerging therapies offer improved prognosis and quality of life for affected individuals.

SMA Typ 2